THERAPY DOSSIER · th-0d45a0b12980

miR-155 hairpin inhibitor (antagomir)

Biologic · miR-155 hairpin inhibitor (antagomir); antisense oligonucleotide.

Evidence & regulatory context

Mechanism: miR-155 hairpin inhibitor (antagomir); antisense oligonucleotide.
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30225790 ↗2019Reported benefit

Inhibition of miR-155 Limits Neuroinflammation and Improves Functional Recovery After Experimental Traumatic Brain Injury in Mice.

MouseTBIControlled cortical impactC57Bl/6MaleIntracerebroventricular0.5 nmol for acute single administration; 0.5 nmol/day for…Acute arm given immediately after injury; delayed arm beginning 24 hours post-i…

Model: Controlled cortical impact traumatic brain injury

TBI robustly increased cortical and microglial/macrophage miR-155 expression; acute ICV antagomir attenuated neuroinflammatory markers at 1 and 7 days and reduced spatial working memory impairment, while delayed ICV infusion attenuated neuroinflammatory markers at 7 days, limited NOX2 changes, redu…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…